Sacituzumab tirumotecan plus anlotinib for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted drugs—sacituzumab tirumotecan and anlotinib—for people with triple-negative breast cancer that has spread or cannot be removed by surgery and has already been treated with at least one prior therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have triple-negative breast cancer that has spread or cannot be removed surgically and has been treated with at least one prior standard therapy.
- You are generally active and able to care for yourself (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your cancer has gotten worse or you cannot tolerate the side effects of your last treatment.
- You have adequate liver, kidney, and bone marrow function (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug called Sacituzumab Tirumotecan given before surgery to women with an aggressive type of early-stage breast cancer (triple-negative breast cancer, or TNBC). The goal is to see if it can improve treatment outcomes.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a combination of two drugs—an antibody-drug conjugate that targets a protein on cancer cells and an immunotherapy that helps your immune system attack the tumor—for people with advanced triple-negative breast cancer that has already been treated. It aims to see if this combo can shrink tumors or slow the disease.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.